Company: ABBV
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001104659-25-014554
Chunk: 19

Company: AbbVie Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 19
---
 than 60 days before the redemption date to each holder of Notes to be redeemed.

In the case of a partial redemption of any series of Notes, selection of the Notes of such series for redemption will be made pro rata, by lot or by such other method as the Trustee in its sole discretion deems appropriate and fair. No Notes of a principal amount of $2,000 or less will be redeemed in part. If Notes of any series are to be redeemed in part only, the notice of redemption that relates to such Note will state the portion of the principal amount of the Notes of such series to be redeemed. A new Note in a principal amount equal to the unredeemed portion of the relevant Note will be issued in the name of the holder of the Note upon surrender for cancellation of the original Note. For so long as the Notes are held by the DTC (or another depositary), the redemption of the Notes shall be done in accordance with the policies and procedures of the depositary. Any redemption or notice of redemption may, at AbbVie’s discretion, be subject to one or more conditions precedent, and, at AbbVie’s discretion, the redemption date may be delayed until such time as any or all such conditions shall be satisfied.

Unless we default in payment of the redemption price, on and after the redemption date interest will cease to accrue on the Notes or portions thereof called for redemption.

#### Open Market Purchases
AbbVie or any of its affiliates may at any time and from time to time purchase Notes in the open market or otherwise.

#### Sinking Fund
There is no provision for a sinking fund for any of the Notes.

#### Ranking
The Notes will be the Issuer’s unsecured, unsubordinated obligations, and will:

•

rank equally in right of payment with all of the Issuer’s existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations;

•

rank senior in right of payment to all of the Issuer’s future indebtedness that is subordinated to the Notes;

<div align='center'>S-14</div>

TABLE OF CONTENTS

•

be effectively subordinated in right of payment to all of the Issuer’s existing and future secured indebtedness, to the extent of the value of the assets securing such indebtedness; and

•

be structurally subordinated in right of payment to all existing and future indebtedness, liabilities and other obligations of the Issuer’s subsidiaries.

AbbVie derives substantially all of its operating income from, and holds